Open House rebate agreements for biologics 2026-23 - Darbepoetin alfa

Summary

The tender concerns rebate agreements for medicines containing the active substance darbepoetin alfa. It is a TK open-house procedure in which contracts are concluded on uniform terms with all suitable pharmaceutical companies; no individual negotiations are held and no exclusivity is granted. The contract term is up to 24 months starting on 01/08/2026 and ends no later than 31/07/2028. The detailed participation and contract conditions must be checked in the tender documents.